These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 34612154)

  • 1. Efficacy of ibrutinib as salvage treatment in a secondary central nervous system lymphoma (SCNSL) progressed after chemorefractory Primary Mediastinal B Cell Lymphoma (PMBCL).
    Malfona F; Testi AM; Moleti ML; Petrucci L; Leccisotti L; Martelli M; Di Rocco A
    Leuk Lymphoma; 2022 Feb; 63(2):483-486. PubMed ID: 34612154
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment with temozolomide and ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL).
    Renaud L; Bossard JB; Carpentier B; Terriou L; Cambier N; Chanteau G; Escure G; Tilmont R; Barbieux S; Wemeau M; Hieulle J; Boyle EM; Morschhauser F
    Eur J Haematol; 2021 Sep; 107(3):370-373. PubMed ID: 34018260
    [No Abstract]   [Full Text] [Related]  

  • 3. Ibrutinib in primary central nervous system diffuse large B-cell lymphoma.
    T Low J; B Peters K
    CNS Oncol; 2020 Mar; 9(1):CNS51. PubMed ID: 32141313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience.
    Lewis KL; Chin CK; Manos K; Casey J; Hamad N; Crawford J; Ho SJ; Issa S; Grigg A; Wood P; Gandhi MK; Do B; Nastoupil L; Hawkes EA; Cheah CY
    Br J Haematol; 2021 Mar; 192(6):1049-1053. PubMed ID: 32677095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Combination of ibrutinib and temozolomide for the treatment of newly diagnosed elderly primary central nervous system diffuse large B cell lymphoma: a case report].
    Wang L; Li X; He YZ
    Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):482. PubMed ID: 32654461
    [No Abstract]   [Full Text] [Related]  

  • 6. SOHO State of the Art Updates and Next Questions: Prophylaxis and Management of Secondary CNS Lymphoma.
    Simard J; Roschewski M
    Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):709-717. PubMed ID: 35787364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary central nervous system lymphoma: an unusual presentation.
    Heckmann JM; O'Ryan S; Candy S
    S Afr Med J; 2008 Nov; 98(11):851-2. PubMed ID: 19177889
    [No Abstract]   [Full Text] [Related]  

  • 8. Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis.
    Patrij K; Reiser M; Wätzel L; Pels H; Kowoll A; Herrlinger U; Engert A; Linnebank M; Schackert G; Vogt-Schaden M; Egerer G; Lamprecht M; Batchelor TT; Schlegel U; Schmidt-Wolf IG;
    Ger Med Sci; 2011; 9():Doc11. PubMed ID: 21698087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma.
    Kim SJ; Yoon DH; Kang HJ; Hong JY; Lee HS; Oh SY; Shin HJ; Kong JH; Yi JH; Sakamoto K; Ko YH; Huh J; Lee SS; Takeuchi K; Shin DY; Suh C; Kim WS
    BMC Cancer; 2019 Nov; 19(1):1080. PubMed ID: 31707975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary Mediastinal Large B-Cell Lymphoma As an Incidental Finding: Report of a Case.
    Yönal-Hindilerden İ; Hindilerden F; Arslan S; Doğan İÖ; Nalçacı M
    Turk J Haematol; 2018 May; 35(2):141-142. PubMed ID: 27094863
    [No Abstract]   [Full Text] [Related]  

  • 11. Liposomal-encapsulated doxorubicin supercharge-containing front-line treatment improves response rates in primary mediastinal large B-cell lymphoma and mediastinal gray zone lymphoma.
    Picardi M; Giordano C; Pugliese N; Mascolo M; Varricchio S; Troncone G; Vigliar E; Bellavicine C; Lamagna M; Lisi D; Vincenzi A; Pane F
    Hematol Oncol; 2024 Jan; 42(1):e3242. PubMed ID: 38126215
    [No Abstract]   [Full Text] [Related]  

  • 12. Liposomal-encapsulated doxorubicin supercharge-containing front-line treatment improves response rates in primary mediastinal large B-cell lymphoma and mediastinal gray zone lymphoma.
    Picardi M; Giordano C; Pugliese N; Mascolo M; Varricchio S; Troncone G; Vigliar E; Bellavicine C; Lamagna M; Lisi D; Vincenzi A; Pane F
    Hematol Oncol; 2024 Jan; 42(1):e3247. PubMed ID: 38287530
    [No Abstract]   [Full Text] [Related]  

  • 13. Axicabtagene Ciloleucel Chimeric Antigen Receptor T Cell Therapy in Lymphoma With Secondary Central Nervous System Involvement.
    Novo M; Ruff MW; Skrabek PJ; Lin Y
    Mayo Clin Proc; 2019 Nov; 94(11):2361-2364. PubMed ID: 31685159
    [No Abstract]   [Full Text] [Related]  

  • 14. Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma.
    Liu M; Deng H; Mu J; Li Q; Pu Y; Jiang Y; Deng Q; Qian Z
    Cancer Sci; 2021 Jul; 112(7):2642-2651. PubMed ID: 33932067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid Resolution of Presumed Vitreoretinal Lymphoma With Systemic Ibrutinib Therapy.
    Mathai M; Fein JG
    Ophthalmic Surg Lasers Imaging Retina; 2021 Apr; 52(4):227-230. PubMed ID: 34039188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mediastinal large B-cell lymphoma with rosette formation mimicking thymoma and thymic carcinoid.
    Tsai HW; Yen YS; Chang KC
    Histopathology; 2006 Jul; 49(1):93-5. PubMed ID: 16842255
    [No Abstract]   [Full Text] [Related]  

  • 17. Molecular attributes underlying central nervous system and systemic relapse in diffuse large B-cell lymphoma.
    Isaev K; Ennishi D; Hilton L; Skinnider B; Mungall KL; Mungall AJ; Bakhtiari M; Tremblay-LeMay R; Silva A; Ben-Neriah S; Boyle M; Villa D; Marra MA; Steidl C; Gascoyne RD; Morin R; Savage KJ; Scott DW; Kridel R
    Haematologica; 2021 May; 106(5):1466-1471. PubMed ID: 32817292
    [No Abstract]   [Full Text] [Related]  

  • 18. Promising activity of selinexor in the treatment of a patient with refractory diffuse large B-cell lymphoma and central nervous system involvement.
    Bobillo S; Abrisqueta P; Carpio C; Raheja P; Castellví J; Crespo M; Bosch F
    Haematologica; 2018 Feb; 103(2):e92-e93. PubMed ID: 29242296
    [No Abstract]   [Full Text] [Related]  

  • 19. Clonal evolution in diffuse large B-cell lymphoma with central nervous system recurrence.
    Magnes T; Wagner S; Thorner AR; Neureiter D; Klieser E; Rinnerthaler G; Weiss L; Huemer F; Zaborsky N; Steiner M; Weis S; Greil R; Egle A; Melchardt T
    ESMO Open; 2021 Feb; 6(1):100012. PubMed ID: 33399078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab for refractory primary mediastinal B-cell lymphoma with central nervous system involvement.
    de-la-Fuente C; Nuñez F; Cortés-Romera M; Franch-Sarto M; Ribera JM; Sancho JM
    Hematol Oncol; 2021 Aug; 39(3):419-422. PubMed ID: 33369766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.